Clofazimine pharmacokinetics in novel rifampicin-resistant tuberculosis regimens: an analysis of the endTB and endTB-Q trials

Tuberculosis remains one of the world's most persistent infectious diseases, but a specific form known as rifampicin-resistant tuberculosis poses a particularly difficult challenge. When the bacteria become resistant to rifampicin, a cornerstone drug used for decades, standard treatments fail, requiring doctors to construct complex, multi-drug regimens to fight the infection. Among the tools in this medical arsenal is clofazimine, an antibiotic originally developed to treat leprosy. This drug has a unique behavior inside the human body: unlike most medicines that pass through the system quickly, clofazimine is fat-soluble and tends to accumulate in tissues, lingering for a very long time. Because it is now being used in new, shorter combinations to treat drug-resistant tuberculosis, scientists need to understand exactly how long it stays in the body and how other factors, such as a patient's other health conditions or the other drugs they are taking, might change its behavior. Without this knowledge, it is difficult to predict whether the drug will be effective or if it might linger long enough to cause side effects after treatment has officially ended.

Researchers set out to map the journey of clofazimine through the bodies of people being treated for rifampicin-resistant tuberculosis. They analyzed data from 100 participants across six countries who were enrolled in large clinical trials testing new treatment combinations. These participants took clofazimine daily for nine months alongside other antibiotics. The team collected blood samples at various points during the treatment and continued to take samples for up to six months after the participants stopped taking the medication. By measuring the levels of the drug in the blood over time, the scientists built a detailed picture of how the drug is absorbed, distributed, and eventually cleared from the body. They used computer modeling to see how different characteristics of the patients, such as their age, weight, or whether they also had HIV or diabetes, influenced the amount of drug circulating in their systems.

The study revealed that clofazimine behaves very differently depending on who is taking it and what else they are taking. The researchers found that when clofazimine was given alongside another specific antibiotic called delamanid, the amount of the drug in the blood increased significantly. Conversely, patients living with HIV had lower levels of the drug in their blood, a difference the authors suggest might be related to how HIV or its treatments affect the digestive system and the speed at which the drug is absorbed. The study also identified a strong link with diabetes; patients with this condition cleared the drug from their bodies much more slowly, leading to higher overall exposure. These findings suggest that the standard dose might result in different levels of the drug in the blood for different people, depending on their specific health profile and medication mix.

Perhaps the most striking discovery concerns how long the drug remains in the body after treatment stops. Because clofazimine stores itself in fatty tissues, it does not disappear quickly once the daily pill is no longer taken. The researchers estimated that after a nine-month course of treatment, it takes a median of 2.5 years for the drug to be completely eliminated from the body. This means that for more than half of the patients, the drug is still present in their system long after the infection has been treated. While the drug is known to cause skin discoloration that can last for years, this study provides the first concrete data showing that the drug itself persists for a similar duration. The authors note that this long tail of exposure is important to consider, as it could influence the risk of side effects or the development of drug resistance if the infection is not fully cleared.

The study concludes that while the new treatment regimens are promising, the way clofazimine behaves in the body is complex and varies from person to person. The presence of diabetes, HIV, or the use of delamanid can significantly alter how much of the drug a patient experiences. The researchers emphasize that these results are based on careful modeling and simulation of the data they collected, and they recommend further studies to confirm these associations before changing how doctors prescribe the medication. For now, the work provides a clearer understanding of the invisible timeline of this powerful antibiotic, showing that for many patients, the treatment continues to work inside them for years after the last dose is taken.